Typhonium Plus

Older People With Chronic Leukemia May Benefit From Experimental Agent

Satria Stealth — Fri, 18 May 2012 01:00:00 +0000

The experimental drug ibrutinib (PCI-32765) shows great promise for the treatment of elderly patients with chronic lymphocytic leukemia (CLL), according to interim findings from a clinical trial. The phase I/II trial, co-led by researchers at the Ohio State University Comprehensive Cancer Center – Arthur G.

Personalized Treatment Advances: Testing For Mutations Identified In Squamous Cell Lung Cancer Tumors

Arriful Affandy — Fri, 18 May 2012 01:00:00 +0000

Screening lung cancer tumor samples for cancer-causing, or “driver,” genetic mutations can help physicians tailor patients’ treatments to target those specific mutations…

View post:
Personalized Treatment Advances: Testing For Mutations Identified In Squamous Cell Lung Cancer Tumors

Personalized Treatment Advances: Testing For Mutations Identified In Squamous Cell Lung Cancer Tumors

Arriful Affandy — Fri, 18 May 2012 01:00:00 +0000

Screening lung cancer tumor samples for cancer-causing, or “driver,” genetic mutations can help physicians tailor patients’ treatments to target those specific mutations…

Personalized Treatment Advances: Testing For Mutations Identified In Squamous Cell Lung Cancer Tumors

Arriful Affandy — Fri, 18 May 2012 01:00:00 +0000

Screening lung cancer tumor samples for cancer-causing, or “driver,” genetic mutations can help physicians tailor patients’ treatments to target those specific mutations…

See original here:
Personalized Treatment Advances: Testing For Mutations Identified In Squamous Cell Lung Cancer Tumors

Personalized Treatment Advances: Testing For Mutations Identified In Squamous Cell Lung Cancer Tumors

Arriful Affandy — Fri, 18 May 2012 01:00:00 +0000

Screening lung cancer tumor samples for cancer-causing, or “driver,” genetic mutations can help physicians tailor patients’ treatments to target those specific mutations…

View original post here:
Personalized Treatment Advances: Testing For Mutations Identified In Squamous Cell Lung Cancer Tumors

Patients With Muscle-Invasive Bladder Cancer Benefit From Accelerated Chemotherapy Given Before Surgery

Satria Stealth — Fri, 18 May 2012 01:00:00 +0000

For some patients with muscle-invasive bladder cancer, treatment may begin before they undergo cystectomy, or surgical removal of the bladder. They may be advised by oncologists to receive chemotherapy before surgery…

Go here to read the rest:
Patients With Muscle-Invasive Bladder Cancer Benefit From Accelerated Chemotherapy Given Before Surgery

Glioblastoma Classification Revision Should Improve Patient Care

Norma Coates — Fri, 18 May 2012 01:00:00 +0000

Radiation oncology researchers have revised the system used by doctors since the 1990s to determine the prognosis of people with glioblastoma, which is the most devastating of malignant brain tumors. The outdated system was devised for glioblastoma and related brain tumors that were treated by radiation therapy only, and it relied on clinical signs and symptoms…

Follow this link:
Glioblastoma Classification Revision Should Improve Patient Care

Glioblastoma Classification Revision Should Improve Patient Care

Norma Coates — Fri, 18 May 2012 01:00:00 +0000

Make Or Break For Cellular Tissues

Norma Coates — Fri, 18 May 2012 00:00:00 +0000

Models developed to study liquids are used to investigate the mechanics of cellular tissues, which could further our understanding of embryonic development and cancer In a study about to be published in EPJ EÂ¹, French physicists from the Curie Institute in Paris have demonstrated that the behaviour of a thin layer of cells in contact with an unfavourable substrate is akin…

See the rest here:
Make Or Break For Cellular Tissues

Lapatinib Combined With Cetuximab Overcomes Resistance In EGFR-Driven Tumors

Arriful Affandy — Fri, 18 May 2012 00:00:00 +0000

Targeted therapies have been studied for years, but recent laboratory research is providing robust clues about drugs that might work better in combination, particularly in treating cancers that have become resistant to therapy. That kind of information is behind a novel clinical trial at Georgetown Lombardi Comprehensive Cancer Center that combines cetuximab and lapatinib…

Excerpt from:
Lapatinib Combined With Cetuximab Overcomes Resistance In EGFR-Driven Tumors